A3P Biomedical: A3P Biomedical appoints Christopher O’Connell as Board Director
22 maj, 14:35
A3P Biomedical AB (publ) (A3P) is pleased to announce the appointment of Christopher O’Connell, who brings exceptional strategic and operational experience to the company, as Board Director.
Christopher O’Connell is a highly regarded senior executive, board member and advisor, with more than three decades of leadership experience across the medical devices, life sciences and global healthcare industries. He built his career over two decades at Medtronic, serving in multiple business areas and functions during an era of rapid expansion, most recently as President of its Restorative Therapies Group. He was also a member of the Medtronic Executive Committee for nine years.
Christopher O’Connell then became CEO and President of Waters Corporation, which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations.
The appointment of Christopher O’Connell comes at a pivotal time as A3P focuses on expanding its pioneering Stockholm3 test for screening and early prostate cancer detection to the United States.
“We are thrilled to welcome Chris to the A3P Board. His deep knowledge of the U.S. healthcare ecosystem and proven track record in building world-class diagnostics and MedTech businesses will be instrumental as we scale our operations with the aim of making Stockholm3 the new global standard of care for prostate cancer screening”, said Martin Steinberg, Executive Chairman.
“Stockholm3 has the potential to transform how prostate cancer is screened and managed in the United States. It’s novel combination of advanced biomarkers and genetics into a single blood test, as well as its proven effectiveness in over 90,000 men studied, creates a unique opportunity to create a new standard of care for prostate cancer screening - detecting more aggressive cancers earlier while reducing unnecessary procedures. I’m excited to join A3P’s mission to bring this important innovation to men across the U.S. and around the world,” said Christopher O’Connell.
For additional information, please contact:
Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Image Attachments
Attachments
A3P Biomedical appoints Christopher O’Connell as Board Director
A3P Biomedical: A3P Biomedical appoints Christopher O’Connell as Board Director
22 maj, 14:35
A3P Biomedical AB (publ) (A3P) is pleased to announce the appointment of Christopher O’Connell, who brings exceptional strategic and operational experience to the company, as Board Director.
Christopher O’Connell is a highly regarded senior executive, board member and advisor, with more than three decades of leadership experience across the medical devices, life sciences and global healthcare industries. He built his career over two decades at Medtronic, serving in multiple business areas and functions during an era of rapid expansion, most recently as President of its Restorative Therapies Group. He was also a member of the Medtronic Executive Committee for nine years.
Christopher O’Connell then became CEO and President of Waters Corporation, which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations.
The appointment of Christopher O’Connell comes at a pivotal time as A3P focuses on expanding its pioneering Stockholm3 test for screening and early prostate cancer detection to the United States.
“We are thrilled to welcome Chris to the A3P Board. His deep knowledge of the U.S. healthcare ecosystem and proven track record in building world-class diagnostics and MedTech businesses will be instrumental as we scale our operations with the aim of making Stockholm3 the new global standard of care for prostate cancer screening”, said Martin Steinberg, Executive Chairman.
“Stockholm3 has the potential to transform how prostate cancer is screened and managed in the United States. It’s novel combination of advanced biomarkers and genetics into a single blood test, as well as its proven effectiveness in over 90,000 men studied, creates a unique opportunity to create a new standard of care for prostate cancer screening - detecting more aggressive cancers earlier while reducing unnecessary procedures. I’m excited to join A3P’s mission to bring this important innovation to men across the U.S. and around the world,” said Christopher O’Connell.
For additional information, please contact:
Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com
About A3P Biomedical
A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com
About Stockholm3
Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.
Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.
Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/
About prostate cancer
Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.
Image Attachments
Attachments
A3P Biomedical appoints Christopher O’Connell as Board Director
-992x558.webp&w=3840&q=75)
Analyser
USA
Klarnas IPO
Novo Nordisks sparpaket
Analyser
USA
Klarnas IPO
Novo Nordisks sparpaket
Marknadsöversikt
1 DAG %
Senast
1 mån
